Subscribe
handshake-agreement
Rawpixel.com / Shutterstock, Inc
17 November 2016Americas

BMS and Enterome collaborate over immuno-oncology

Bristol-Myers Squibb and Enterome, a pharmaceutical development and diagnostic company, have entered into a collaboration agreement focusing on immuno-oncology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
BMS sues over generic of blockbuster leukaemia treatment
4 October 2021   Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.
Americas
BMS pays $1.85bn for immuno-oncology programme
15 February 2018   Bristol-Myers Squibb has agreed to pay $1.85 billion for an immuno-oncology programme.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
BMS sues over generic of blockbuster leukaemia treatment
4 October 2021   Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.
Americas
BMS pays $1.85bn for immuno-oncology programme
15 February 2018   Bristol-Myers Squibb has agreed to pay $1.85 billion for an immuno-oncology programme.

More on this story

Americas
BMS sues over generic of blockbuster leukaemia treatment
4 October 2021   Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.
Americas
BMS pays $1.85bn for immuno-oncology programme
15 February 2018   Bristol-Myers Squibb has agreed to pay $1.85 billion for an immuno-oncology programme.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB